FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
VioQuest Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for VioQuest Pharmaceuticals, Inc. (VOQP) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVOQP
VOQP
VioQuest Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
VOQP
Home🔹Stocks🔹VioQuest Pharmaceuticals, Inc.

VioQuest Pharmaceuticals, Inc.

VOQP•OTC

VioQuest Pharmaceuticals, Inc.

VOQP•OTC
Market cap
$14.72K
Sentiment

Your view on VOQP

Mkt Cap
$14.72K
Sentiment
Your view
VOQP
VioQuest Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
VOQP
Company Overview

Overview

What the company does, where it operates, and who runs it.

About VioQuest Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Mark D. Dacko
Headquarters
180 Mount Airy Road, Basking Ridge, NJ, US
Industry
Biotechnology
Sector
Healthcare
CEO
Mark D. Dacko
Headquarters
180 Mount Airy Road, Basking Ridge, NJ, US
Description

VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News